
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Please fill in all required fields for a chance to win a Kindle and to download special advertising information for the Pharmaceutical Executive 30th Anniversary issue.






